Overview of Nephronophthisis: A Genetically Heterogeneous Ciliopathy

Vimal Master Sankar Raj**, Roberto Gordillo1,2, Diana Warnecke1 and Deepa H Chand1,2

1University of Illinois College of Medicine at Peoria, USA
2AbbVie Inc. North Chicago, Illinois, USA

*Corresponding author: Vimal Master Sankar Raj, Division of Pediatric Nephrology, University of Illinois College of Medicine, Peoria, USA, Tel: +(309)624-9844; Fax: +(309) 624-8884; E-mail: vraj@uicomp.uic.edu

Abstract

Data sources: A literature review was conducted using pubmed database. English language articles published over the past 25 years in peer reviewed journals were reviewed – search terms used “Nephronophthisis”, “Cilia”, “Ciliopathy” and “Cystic Kidney disease”. A total of 34 articles were available of which 8 were review articles and 26 were that of clinical and animal trials. Additional information was also obtained from the references in select review articles. 4 articles (clinical trials) were excluded as they pertained to adult medullary cystic kidney disease.

Nephronophthisis (NPHP) is an autosomal recessive cystic renal disease which presents with chronic tubulointerstitial nephritis and progressive renal failure. If extrarenal symptoms are present in addition to NPHP; these disorders are classified as NPHP-related ciliopathies (NPHP-RC).

Recent identification of many disease causing genes have improved our understanding of ciliopathies and their varied presentation involving multiple organ systems. The piliotropy in NPHP is explained by the fact that almost all NPHP gene products share expression in primary cilia, a sensory organelle present in most mammalian cells. Genetic testing for the most common affected genes is readily available making the diagnosis process easier and without the need for invasive procedures such as renal biopsy.

Even though major breakthrough has been achieved in identifying new pathogenic genes, still known genetic diagnosis is available only in about 30 to 40% of NPHP-RC. Current treatment options are only supportive and all children with NPHP will progress to ESRD requiring renal replacement at some point in their life.

The challenge still remains to understand the biological function of nephrocystins and the molecular mechanism behind cyst formation. Further research to understand the biology of cyst formation at a cellular level and the molecular role of the other pathogenic genes will help improve our understanding of this complex disease. This could hopefully provide us with tools to delay progression or even reverse the process of cyst formation and hence renal failure in NPHP. We report here a case of a young adolescent boy diagnosed with NPHP, his clinical presentation and management with a brief literature review on this rare genetic cause of ESRD.

Case Study

The patient is a 12 year old Caucasian boy who presented to his primary care physician with h/o fatigue, lethargy, low grade fevers and vomiting. His past medical history was significant for primary nocturnal enuresis and constipation. For the enuresis patient has seen an urologist and was started on desmopressin about 4 years back. Prior lab works included a urine analysis which showed low specific gravity at 1.005 but no protein or blood. For constipation, patient uses stool softener on and off. No other significant health issues were identified by family. He was one of four siblings and there was no significant family h/o renal disease, dialysis or kidney transplant. The pediatrician did lab work including a complete blood count and chemistry panel which showed the following values. Hemoglobin 8.2 g/dL, Hematocrit 23%. Sodium 140 meq/L, potassium 4 meq/L, chloride 109 meq/L, bicarbonate 20 meq/L , blood urea nitrogen 90 mg/dL, creatinine 4.1 mg/dL, calcium 8.1 mg/dL and phosphorus 6.1 mg/dL.

Patient got admitted under pediatric nephrology service in Children’s hospital for further evaluation. Physical examination showed a height of 146 cm, body weight of 34 kg, and blood pressure of 114/66 mm Hg with a regular heart rate of 90 beats per minute. On exam no edema was appreciated. Visual acuity was normal and an ophthalmologist assessment did not show any retinal abnormalities. Neurological exam was intact and no skin rash or joint swelling appreciated. Further work up included complements (C3 & C4) which were in the normal limits, Parathyroid hormone elevated at 966 pg/ml indicating chronic kidney damage and vitamin D level was adequate at 27 ng/ml. Urine analysis was repeated and showed bland urine with low specific gravity 1.005 and no protein or blood. Urine protein/Creatinine ratio was normal at 0.2 and fractional excretion of sodium was elevated at 7.6% indicating intrinsic renal injury.

Imaging studies included a renal ultrasound which showed both kidneys to measure around 10 cm (normal for age) with increased echogenicity and no hydronephrosis. A voiding cyst urethrogram (VCUG) did not reveal any reflux. Radionuclide studies included a MAG3 scan which showed slow uptake of the radiotracer with cortical retention and slow delayed excretion compatible with chronic medical renal disease. A clinical diagnosis of cystic kidney disease was made and molecular testing for NPHP 1 gene done. Patient’s acidosis was corrected with bicarbonate supplementation and epogen was started for anemia. The molecular testing did come back positive for NPHP1 homozygous deletion confirming the diagnosis of nephronophthisis. Patient was placed on a preemptive renal transplant list and is now s/p a diseased donor kidney transplant with normal renal function. Screening on his other siblings showed that one of his younger brothers, an eight year old boy also has NPHP with elevated creatinine and is currently getting medically managed for his chronic kidney disease.

Copyright: © 2016 Raj VMS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background

Nephronophthisis (NPHP) is an autosomal recessive condition leading to cystic kidney disease and is a leading genetic cause of renal failure in young children and adolescents [1]. The incidence of NPHP varies worldwide from 1 in 50,000 to 1 in 900,000 children with a reported prevalence of 5% among pediatric end stage renal disease (ESRD) patients in the United States [2]. Because of shared morphological features, autosomal dominant medullary cystic kidney disease (MCKD) and NPHP are often described together. The key difference between NPHP and MCKD is age of onset. The median age of ESRD due to NPHP is 13 years, while MCKD usually progresses to ESRD in adulthood.

NPHP is a genetically heterogeneous disease with 13 identified genetic mutations accounting for 30% of all affected patients [3]. The protein products of most of the mutated genes localize to the primary cilium in accordance with the concept of ciliopathies. Infantile NPHP has been linked to NPHP2 mutations, while the more common juvenile form has mutations in several genes including NPHP 1, 4, 5 and 6. Mutation in Nephrocystin-1 (NPHP1) accounts for majority of isolated cases of NPHP [4,5].

A variety of extra renal manifestation can occur with NPHP including retinitis pigmentosa, ocular motor apraxia, cerebellar vermis hypoplasia, occipital encephalocele, coloboma of the optic nerve, Leber congenital amaurosis (LCA), hepatic fibrosis and situs inversus illustrating the multitude of downstream effects of ciliopathies. A brief description of the syndromes associated with NPHP and extra renal features common in these syndromes is described below.

Bardet-Biedl syndrome (BBS)

BBS is a rare autosomal recessive ciliopathy with incidence ranging from 1 in 140,000 live births in North America to 1 in 13,500 live births in Kuwait, where consanguinity is more common [6]. Sixteen different BBS gene mutations have been identified, with the predominant genotypes of disease being BBS1 and BBS10 [7]. Clinical features involve multiple organs and include postaxial polydactyly and progressive loss of vision due to rod cone dystrophy [8]. Obesity is present in majority of patients with one third of patients becoming obese by one year of age [9]. Hypogonadism and infertility are usually present. Renal involvement contributes to the majority of mortality and morbidity in these patients and can present with varying degrees of dysplasia and cystic disease.

The varying gene products in BBS localize near the basal body of the primary cilium and are involved in the formation of BBSome and cilia structure and function. These in turn interact with BBS3 (GTPase protein) and rab7 facilitating formation and maintenance of cilia [10].

Joubert syndrome and Joubert syndrome related disease (JS, JSRD)

JS is an autosomal recessive inherited condition with incidence ranging from 1 in 80,000 to 1 in 100,000 live births; and is characterized by the hallmark finding of “molar tooth sign” on brain imaging secondary to a complex midbrain-hindbrain malformation [11,12]. The neurological features include varying degrees of hypotonia, ataxia, developmental delay, oculomotor apraxia, nephrosis and neonatal breathing dysregulation with alternating episodes of hyperpnea and apnea. As with the clinical features of other ciliopathies, multi-organ involvement mainly retinal dystrophy, LCA, nephronophthisis, hepatic fibrosis and polydactyly are often present. Renal involvement is present in about 25% of patients with JS.

Ten causative genes have been identified (JBTS 1 to 10) which localize to the primary cilia. Genetic and clinical overlap with other syndromes especially Meckel Gruber syndrome (MKS) is seen. Genetic mutations which contribute to the majority of JSRD and their associated clinical features are presented in Table 1.

Senior-loken syndrome (SLS)

The association of NPHP with retinal degeneration is referred to as SLS, which can occur independently or as a part of JS. Two variants of retinal disorder namely Leber congenital amaurosis (LCA) and tapetoretinal degeneration can occur with SLS [13]. Leber congenital amaurosis is the most severe variant and can present with profound loss of vision, nystagmus with varying degrees of atrophy and pigmentary changes in the retina. Tapetoretinal degeneration is a milder variant and it presents with tube like restriction of visual field and varying degree of pigmentary alteration in the retinal field.

Mekel gruber syndrome (MKS)

MKS is a lethal autosomal recessive disease with incidence ranging from 1 in 13,250 to 1 in 140,000 live births with predilection for Belgian and Finnish populations [14]. It is characterized by a triad of malformations, usually occipital encephalocele, cystic dysplasia of the kidneys and post axial polydactyly [15,16]. Six different genes have been identified up to date (MKS1 to 6) which localize to the primary cilia and play a role in the structure and proper function of cilia [17].

Boichis syndrome and RYHNS syndrome

The association of nephronophthisis with congenital hepatic fibrosis has been described as Boichis syndrome [18]. Association of NPHP with varying degree of retinal involvement, skeletal dysplasia and pituitary deficiency is called the RYHNS (Retinitis pigmentosa, Hypopituitarism, Nephronophthisis and Skeletal dysplasia) syndrome [19].

Cogan syndrome

Cogan syndrome is an autosomal recessive condition which presents with ocular motor apraxia with defective horizontal eye movements and nystagmus. Patients with Cogan syndrome can have cerebellar vermis hypoplasia [20]. Deletions and point mutations in NPHP 1 gene of patients with Cogan syndrome can have cerebellar vermis hypoplasia as well [21].

Jeune syndrome or Asphyxiating Thoracic Dystrophy (ATD)

Jeune syndrome or ATD is an autosomal recessive osteochondrodysplasia with characteristic skeletal abnormalities including narrow thorax, short ribs, short bones in arms and legs, polydactyly and short stature [22]. Varying degrees of renal, hepatic, pancreatic and retinal complications occur in children who survive beyond the first few years of life. Renal involvement occurs in about 30% of patients and includes varying degrees of cystic dysplasia, hypertension and progressive renal insufficiency. Genes mutated in Jeune syndrome (IFT80 and DYNCH1) play a main role in intra flagellar transport and hence essential for maintenance of ciliary structure and function.

Genetic basis of NPHP

A growing number of genes have been implicated in NPHP, inherited in an autosomal recessive manner (Table 2). Oligogenicity, in which allelic variants at multiple locations can contribute to the disease, and epistasis in which modifier genes can alter phenotype, have been identified with NPHP [23,24]. Oligogenicity and epistasis explains the wide spectrum of clinical variation that can be associated with any mutant gene in NPHP.

NPHP1: NPHP1, which accounts for approximately 25% of nephronophthisis cases, was the first gene identified to cause this group of diseases [25]. Most common among NPHP1 mutation is homozygous deletion at 2q13 [26]. Most common extra renal manifestation with NPHP1 mutation includes SLS, JSRD and Cogan syndrome [27-29]. The protein product of NPHP1, namely nephrocystin-1, is expressed predominantly in the renal collecting ducts [30] and localizes to the primary cilium and epithelial cell adherens junctions [31,32].
NPHP2: Mutations in NPHP2 give rise to infantile NPHP and account for <1% of cases [33]. NPHP2/INV is located in 9q31. The protein product inverson is localized in the primary cilium and other subcellular sites dynamically based on the stage of cell cycle [34]. Extra renal manifestations include situs inversus, ventricular septal defect, hepatic fibrosis and rarely SLS [35]. In addition to its proposed mechanism of acting as a switch between canonical and non-canonical Wnt pathway, inverson plays a role in maintenance of tubular architecture via planar cell polarity signaling [36].

NPHP3: NPHP3 mutations are rare, accounting for <1% of cases. A variety of extra renal phenotype including SLS, MKS and situs inversus can be present. NPHP3 gene encodes for protein nephrocystin-3 and is located in 3q22.1 [37]. Nephrocystin-3 localizes to the primary cilium and interacts with both nephrocystin-1 and inverson [38].

NPHP4: NPHP4 which encodes nephrocystin-4 or nephroretinin has a mutation frequency of 2 to 3% in genetically confirmed NPHP with the abnormality located in 1p32.2 [39,40]. Nephrocystin-4 localizes to the primary cilium and interacts with other proteins namely nephrocystin-1, 3,8 and inversin. Retinitis pigmentosa is the most common extra renal phenotype associated with NPHP4 mutation explaining the name nephrocystin and its association with retinal ciliopathy gene retinitis pigmentosa GTPase regulator (RPGR).

NPHP5: Mutations in NPHP5 affect nephrocystin-5, which contains two IQ calmodulin binding sites located in 3q21.1 [41]. NPHP5 mutations cause early onset retinal degeneration. Nephrocystin-5 co-localizes with nephrocystin-1 and nephroretinin-4 in the primary cilium. Nephrocystin-5 is similar to nephroretinin in that it complexes with RPGR explaining the retinal involvement.

NPHP6: Mutations in NPHP6 also known as Centrosomal Protein 290 (CEP290) is located in 12q21.32 [42]. Mutations in NPHP6 account for differing clinical phenotypes including isolated NPHP, SLS, JS, MKS and BBS. NPHP6 is also the most common isolated mutation seen in Leber's congenital amaurosis [43]. The varying clinical phenotypes with NPHP6 mutations have been suggested to be secondary to its oligogenicity.

NPHP6 also interacts with other transcription factors such as TF4 which is involved in renal cyst formation and coiled-coil and c2 domain protein (CC2DA) [44]. CC2DA mutations have been noted in JS and MKS [45].

NPHP7/GLIS2: NPHP7 encodes GLI similar 2 protein (GLIS2) and is located in 16p13.3 [46]. GLIS2 localizes to the primary cilium and nucleus.

NPHP8/RPGRIP1L: NPHP8 encodes retinitis pigmentosa GTPase regulator interacting protein 1-like and is located in 16q22.2 [47]. NPHP8 mutations often cause extra renal manifestations such as JS, MKS and cerebello-oculo-renal syndrome. RPGRIP1L co-localizes with nephrocystin-4 and 6 at the basal bodies and centrosomes [48].

NPHP9/NEK8: NPHP9 encodes NIMA-kinase 8 (NEK8) protein and is located in 17q11.1 [49]. NEK8 co-localizes with various nephrocystins in primary cilium and also has shown interaction with polycystin-2 [50]. Although a rare cause for NPHP, NPHP9 mutation has been shown to cause both infantile and non-infantile NPHP.

NPHP10/SDCCAG8: NPHP10 encodes Serologically Defined Colon Cancer Antigen 8 (SDCCAG8) and is located in 1q44 [51]. SDCCAG8 co-localizes with nephrocystin-5, encoded by NPHP5, in centrosomes and the cell-cell junction of the primary cilium. It also interacts with retinal ciliopathy proteins such as RPGRIP1L. The encoded by NPHP8. Though a rare cause for isolated NPHP, SDCCAG8 mutations have been noted in SLS and BBS.

NPHP11/TMEM67: NPHP11 encodes trans-membrane protein 67 (TMEM67) and is located in 8q22.1 [52]. NPHP11 mutations have been noted in patients with NPHP and liver fibrosis and other ciliopathies such as JS and MKS. TMEM67 localizes to the primary ciliary membrane and plays an important role in maintaining ciliary cellular structure.

Mutations have also been identified in protein products other than ciliary proteins such as X-propyl aminopeptidase (XPNPEP3) which localize to mitochondria in two consanguineous families with NPHP [53]. Additional extra renal manifestations noted in the affected family include cardiomyopathy and seizures. Another rare mutation linked to retrograde intracellular transport (IFT139) has also been identified in some families with NPHP [54].

Table 1: Genetic defect in JSRD [11]

<table>
<thead>
<tr>
<th>RD: Retinal dystrophy; PM: Polymicrogyria; NPHP: Nephronophthisis; OMA: Oculo motor apraxia; LCA: Leber congenital amaurosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPHP type</td>
</tr>
<tr>
<td>NPHP1</td>
</tr>
<tr>
<td>NPHP2</td>
</tr>
<tr>
<td>NPHP3</td>
</tr>
<tr>
<td>NPHP4</td>
</tr>
<tr>
<td>NPHP5</td>
</tr>
<tr>
<td>NPHP6</td>
</tr>
<tr>
<td>NPHP7</td>
</tr>
<tr>
<td>NPHP8</td>
</tr>
<tr>
<td>NPHP9</td>
</tr>
<tr>
<td>NPHP10</td>
</tr>
<tr>
<td>NPHP11</td>
</tr>
</tbody>
</table>

Table 2: Genetic defect and mutated protein in NPHP

<table>
<thead>
<tr>
<th>SLS: Senior Loken syndrome; JS: Joubert syndrome; MKS: Meckel Gruber syndrome; LCA: Leber Congenital amaurosis; BBS: Bardet Biedl Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPHP type</td>
</tr>
<tr>
<td>NPHP1</td>
</tr>
<tr>
<td>NPHP2</td>
</tr>
<tr>
<td>NPHP3</td>
</tr>
<tr>
<td>NPHP4</td>
</tr>
<tr>
<td>NPHP5</td>
</tr>
<tr>
<td>NPHP6</td>
</tr>
<tr>
<td>NPHP7</td>
</tr>
<tr>
<td>NPHP8</td>
</tr>
<tr>
<td>NPHP9</td>
</tr>
<tr>
<td>NPHP10</td>
</tr>
<tr>
<td>NPHP11</td>
</tr>
</tbody>
</table>

Role of Cilia in Cystic Kidney Disease

Cilia are finger-like projections from the surface of cell with a modified cell membrane. Cilia are motile structures derived from primary cilium. Cilia and primary cilium are present in a wide variety of vertebrate cell types except for lymphocytes and enterocytes. They can detect a variety of mechanical, osmotic, photonic and olfactory stimuli and play a role in controlling cell cycle and polarity of epithelial cells.

Primary cilia assemble and disassemble at various stages of the cell cycle. Intraflagellar transport is mediated by transport proteins such as kinesin-2 which promotes anterograde movement while dynein directs retrograde movement. Disruption of transport in either direction will interfere with cilia formation and function [57-59]. As genes involved in varying cystic kidney diseases were identified with positional cloning, it was observed that the mutated proteins localize to varying parts of primary cilium, centrosome and basal bodies [60]. This lead to evolution of a new disease concept, namely ciliopathy, thus linking the role of malformed and malfunctioning cilia to renal cystic disease. The proposed mechanisms linking cilia and cyst formation can be classified into the following:

1. Intact cilia and polycystin 1 and 2 are shown to be essential in flow induced calcium release from the endoplasmic reticulum in cultured Madin-Darby canine kidney cells through ryanaudine and inosine triphosphate (IP3) receptors [61-63]. This indicates the role of polycystins as a sensory modulator in cilia. Lower intracellular calcium has been postulated to reduce clearance of intracellular cAMP which in turn can cause increased cell proliferation and abnormal fluid secretion leading to cyst formation [64].

2. The role of mammalian target of rapamycin (mTOR) in cyst formation came to light with identification of tuberous sclerosis genes (TSC1 and TSC2) which codes for protein tuberin and hamartin respectively. TSC1 like polycystin also localizes to the cilium [65-67]. TSC1 and TSC2 forms a complex with a small GTP binding protein namely Rheb and this in turn is inhibited by phosphatidyl inositol 3 kinase/protein kinase B (PI3K/Akt or PAkt) signaling. The mTOR complex (mTORC1) which activates varied cellular processes such as growth and proliferation is inhibited by TSC1/TSC2/Rheb complex while phosphorylation of TSC2 by PAkt signaling will indirectly activate mTORC1. Uninhibited mTORC activity could result in reduced apoptosis and abnormal cell proliferation and subsequent formation of cyst.

3. Primary cilia and the cytoskeletons play a main role in Wnt signaling pathways, a deregulation of which can contribute to cyst formation. Wnt signaling pathways are classified into canonical and non-canonical pathways. The initiation process for Wnt signaling involves interaction of Wnt ligands with specific Frizzled (Fz) receptors which recruits intracellular Dishevelled proteins (Dvl) and further co-receptor activation [68,69]. The canonical pathway involves binding of three morphogens namely sonic (Shh), Indian (Ihh) and Desert (Dhh) to its receptor Patched 1 (Ptc1). The ligand receptor interaction derepresses and activates transcriptional factors such as Gli 2 and Gli 3 [73,74]. Mutations in ciliary proteins can cause abnormal HH activity and can lead to abnormal renal development. Reduced Hh signaling has been shown to be associated with ectopic kidney and cyst formation in mice [75] while Ihh has been found to be upregulated in a corticosteroid induced models of renal cyst [76].

Evaluation and Screening Strategies

Early presenting features in NPHP are usually subtle and are secondary to impaired concentrating ability of the kidneys. Initial presentation often includes polyuria, nocturia, polydipsia and secondary enuresis. Anemia and lethargy presents early in the disease. Early morning urine will be inappropriately dilute due to the inability to concentrate in the setting of water restriction [77]. Gradual deterioration of renal function occurs with progression to ESRD by adolescence in juvenile NPHP. In the infantile form children may reach renal failure by 3 years of age.

Diagnosis of NPHP relies on a clinical suspicion of the disease. Cystic kidney diseases should be considered in the differential in children presenting with polyuria, polydipsia, enuresis and low urine concentrating ability. Other clinical presentations could include but not limited to complications of renal insufficiency such as nausea, vomiting, fatigue due to anemia and pruritus due to uremia. Blood pressures may be elevated but likely normal in the initial stages secondary to polyuria. Presence of extra renal manifestations such as abnormal eye movements, abnormal renal pigmentation, polydactyly and other neurological manifestations along with a family history of renal disease or consanguinity should alert the clinician to the possibility of a ciliopathy.

Initial investigation would include measurement of first morning urine osmolality and protein/creatinine ratio. Typically proteinuria is minimal or absent and the urine sediment is bland. Low morning urine osmolality indicates defect in urine concentrating ability. Renal function, liver function, complete blood count, and intact parathyroid hormone give essential information in diagnosis and management of chronic kidney disease. An ultrasound of the abdomen will show normal or reduced kidney size usually with increased echogenicity. Cortico-medullary cysts are often present but sometimes may not be sonographically apparent during earlier stages of the disease.

A baseline ophthalmological examination is recommended to evaluate retinal and ophthalmological changes associated with NPHP. Depending on the clinical presentation further neurological imaging and evaluation may be necessary. Ongoing surveillance of growth and development, endocrine function, and sexual maturation in the setting of chronic kidney disease is essential.

Because NPHP1 accounts for the majority of mutations in NPHP, screening in appropriate in children with typical clinical features. NPHP2, NPHP3, and NEK8 screening should be considered if age of presentation is less than 5 years. If a known genetic mutation is identified there is no need for a renal biopsy but should be considered if genetic screening is not available or if mutation is not identified. A diagnostic algorithm for genetic screening in NPHP is presented in figure 1.
Renal biopsy shows severe tubular damage. Tubular basement membrane abnormalities with varying degrees of tubular atrophy and interstitial fibrosis were seen [78]. Very few inflammatory cells are seen and glomeruli are usually normal in the early stages but will go on to have secondary sclerosis with progression of the disease.

**Treatment**

At present there is no definitive cure for NPHP and other related ciliopathies. Management centers on slowing progression of chronic kidney disease with optimal management of fluid balance, hypertension, proteinuria, metabolic bone disease, renal anemia, growth failure and timely renal replacement therapy. But with better understanding of ciliopathies and ongoing trial in animal models we could expect some definitive therapy in slowing renal cyst formation and progression in the future. Drugs of interest include but not limited to vasopressin receptor antagonist, mTOR inhibitors and cyclin dependent kinase inhibitors [79-82] which have been tried with success in animal models of NPHP and ADPKD.

**Conclusion**

Our understanding of the molecular basis of NPHP has improved tremendously over the past decade. The role of primary cilia, cystoproteins in the pathogenesis and the fact that ciliopathies have a wide spectrum of clinical presentation has been learnt. The challenge still remains to understand the biological function of nephrocystins and the molecular mechanism behind cyst formation. Further research and understanding of the biology of cyst formation at a cellular level is necessary to facilitate the development of novel therapy to delay or reverse the disease process.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**References**


